Market Overview

Keryx Biopharmaceuticals Falls After Presentation Of Auryxia Data

Share:
Related KERX
Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says
The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO
Merger Arbitrage Mondays - December 17, 2018 (Seeking Alpha)

Keryx Biopharmaceuticals (NASDAQ: KERX) shares are trading lower by $0.16 at $6.21 in Monday's session.

At this time, investors aren't that impressed with the company's presentation of the positive real world dialysis data of Auryzia presented on Saturday. Auryxia is FDA-approved as a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis and the company is looking to expand its usage.

Auryxia's PDFUA date is scheduled for today.

See Also: Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Keryx's opening print of $6.60 stands as the high for the session as of 10:45 a.m. EST. That level is just shy of its Nov. 1 high of $6.69.

Since reversing course, it surrendered all of its gains trading as low $6.11 and is now attempting to distance itself from that low.

Posted-In: Technicals Intraday Update Movers Trading Ideas

 

Related Articles (KERX)

View Comments and Join the Discussion!

CarGurus Could Be In The Fast Lane To Outperformance

The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket